<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="2211" language="x-unspecified"/>
    <type:ORR xmi:id="13" sofa="6" begin="922" end="927"/>
    <type:ORR xmi:id="17" sofa="6" begin="1050" end="1053"/>
    <type:ORR xmi:id="21" sofa="6" begin="1074" end="1076"/>
    <type:PFSMean xmi:id="25" sofa="6" begin="1220" end="1230"/>
    <type:OSMean xmi:id="29" sofa="6" begin="1269" end="1280"/>
    <type:OSMean xmi:id="33" sofa="6" begin="2056" end="2065"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="BACKGROUND: Capecitabine is a widely accepted option in pre-treated metastatic&#13;&#10;breast cancer (MBC) patients. However, little is known about specific activity in&#13;&#10;molecularly defined subgroups of patients. Here, response, survival and&#13;&#10;prognostic factors were examined in a prospectively characterized cohort of human&#13;&#10;epidermal growth factor receptor 2 (HER2) negative MBC patients receiving&#13;&#10;capecitabine following anthracycline and taxane failure.&#13;&#10;PATIENTS AND METHODS: Medical records from 75 HER2-negative MBC pre-treated with &#13;&#10;anthracycline and/or taxane and receiving capecitabine monotherapy at the&#13;&#10;Institut Paoli-Calmettes between 2002 and 2009 were reviewed. Univariate and&#13;&#10;multivariate analysis according the Cox regression model were employed to&#13;&#10;identify factors predictive for response, progression-free survival (PFS) and&#13;&#10;overall survival (OS).&#13;&#10;RESULTS: Overall, the objective response rate (ORR) was 29.3% (95% CI: 20-40).&#13;&#10;The ORR in HER2-negative/hormonal receptor (HRe) positive and&#13;&#10;HER2-negative/HRe-negative patients were 37% (95% CI: 26-50) and 0% (95% CI:&#13;&#10;0-19), respectively, (p=0.003, Fisher's test). With a median follow-up of 35.2&#13;&#10;months after capecitabine initiation, median PFS was 6.6 months (95% CI:&#13;&#10;4.7-10.4) and median OS was 18.4 months (95% CI:14.1-24.9). In univariate&#13;&#10;analysis, HRe-negative status was the strongest prognostic factor for PFS (hazard&#13;&#10;ratio (HR)=2.09; p-value=0.015, log-rank test). In multivariate analysis, only&#13;&#10;three variables (HRe-negative status, initial disease-free interval &lt;24 months&#13;&#10;and extra-regional lymph node involvement) were considered independently&#13;&#10;associated with poor PFS, while five variables (grade 2/3, initial disease-free&#13;&#10;interval &lt;24 months, central nervous system metastases, interval between&#13;&#10;diagnosis of metastases and capecitabine initiation &lt;24 months, and number of&#13;&#10;metastatic sites on capecitabine initiation) were associated with poor OS.&#13;&#10;CONCLUSION: The median OS of pretreated patients with HER2-negative MBC receiving&#13;&#10;capecitabine is approximately 18 months, but HER2-negative/HRe-negative patients &#13;&#10;have a low probablility of response/disease control to capecitabine and require&#13;&#10;innovative therapies."/>
    <cas:View sofa="6" members="1 13 17 21 25 29 33"/>
</xmi:XMI>
